Truffle Capital

Truffle Capital S.A.S., founded in 2001 and based in Paris, France, is an independent venture capital and private equity firm that specializes in financing innovative startups across various sectors, including information technology, life sciences, and energy. The firm focuses on disruptive technologies, particularly in fintech, insurtech, biomedicine, and medical devices. Truffle Capital primarily invests in European companies with a presence in high-growth regions such as North Africa, the Middle East, India, and Brazil. Its investment strategy includes targeting companies with revenues between €0.1 million and €100 million, and it typically invests amounts ranging from €0.25 million to €80 million per company. The firm prefers to take minority or majority stakes and seeks to hold investments for around five years, often taking board seats to support the growth of its portfolio companies. Over its history, Truffle Capital has raised over $1 billion and has supported more than 75 companies, aiming to nurture future market leaders in their respective fields.

Bozena Adamczyk

Partner, Fintech, Finance Specialist

Mark S. Bivens

Operating Partner

Joseph Boudara

Investor Relations

Alain Chevallier

Senior Partner, BioMedTech

Claire Corot

Senior Partner, Biomedtech

Daniele Genovesi

Partner, Fintech, Expert Intelligence Artificielle

Sneha Hiremath

Head of Investor Relations

Gaetano Insalaco

Chief Financial Officer and Partner

Olga Koulechova

Partner and Head of Investor Relations and Marketing

Patrick Kron

Chairman

Maud Lazare

Director of Investor Relations

Patrick Lord

Senior Partner

Alexandre Ouimet-Storrs

Partner

Antoine Pau

Senior Partner, BioMedTech

Bernard-Louis Roques

Co-Founder, CEO

Eric Séjor

Partner, Biomedtech

50 past transactions

Obat

Seed Round in 2022
Obat supplies contractors and independent contractors with invoicing software. The tool is constantly changing depending on input from customers and partners.

Cachet

Series A in 2022
Cachet is a "trustee" data layer between the sharing economy platforms and insurance providers. We aggregate and enrich cross-market data about how much service providers are providing service on various competing platforms and via that enable insurance companies to sell more personalised coverage. We have started with the ride-hailing/mobility sector since it has the highest number of participants.

RollingFunds

Venture Round in 2022
RollingFunds offers short term financing to small and medium enterprises. The company was founded in 2018 and is headquartered in Paris, France.

Cake App

Seed Round in 2022
Cake App mission is to become the leading software technology provider that analyzes financial data to help people better understand, control and improve their finances, supported by a business model that shares our revenue with users.

IPaidThat

Venture Round in 2021
IPaidThat automatically imports the invoices you receive, and compares them with your bank transactions, to make sure you do not forget anything.

Monisnap

Series A in 2021
Monisnap SAS operates a digital instant money transfer platform and mobile application, enabling users to send money abroad quickly and efficiently. Founded in 2017 and based in Paris, France, the company targets the remittance market, addressing issues such as high fees and low customer satisfaction commonly associated with traditional services. Monisnap allows users to transfer money from Europe to various locations worldwide, facilitating transactions for individuals and businesses alike. The company is authorized to function as a banking intermediary by the French Financial Authority, highlighting its commitment to regulatory compliance and customer trust. Monisnap aims to provide a competitive alternative in the money transfer sector through its user-friendly platform and transparent fee structure.

Zaion

Series A in 2021
Zaion SAS, founded in 2017 and headquartered in Paris, France, specializes in developing integrated solutions for oral and written conversations, including callbots and voicebots. The company focuses on automating customer interactions through its innovative voice customer relationship software and chatbot technology, which enables natural language processing for both calls and text-based conversations. Zaion's offerings facilitate the supervision of customer interactions, provide insightful reporting, and integrate seamlessly with information systems and customer relationship management platforms. As a European expert in customer relationship solutions enhanced by artificial intelligence, Zaion aims to streamline and improve the efficiency of customer service processes.

ACASI

Seed Round in 2021
Acasi SAS develops accounting management software for freelancers. It offers online quotation and invoicing, managing VAT, automatic transmission of your expenses, cash in real time, and automatic accounting management. The company was incorporated in 2017 and is based in Paris, France.

MoneyTrack

Series A in 2021
MONEYTRACK SAS provides a blockchain-based directed payment platform for insurance reimbursement services. Its platform validates payment contracts between financiers, issuers, beneficiaries, merchants, and payment institutions in the directed payment chain. The company was founded in 2018 and is based in Paris, France.

Smile&Pay

Series B in 2021
Smile&Pay SAS, founded in 2007 and based in Paris, France, specializes in card payment solutions tailored for smartphones and tablets. The company provides electronic payment terminals designed for small and medium-sized merchants, enabling them to accept payments from a broad customer base without any fixed fees. Its product lineup includes PocketSmile, a compact mobile terminal that accepts all credit cards, and MaxiSmile, which features a printer and mobile GPRS capabilities. Additionally, Smile&Pay offers a service that allows users to track their receipts in real time through their computers or smartphones, catering to contractors, retailers, and the self-employed.

Particeep

Venture Round in 2021
Particeep is a fintech that provides banks, asset management firms, insurances and their distributors an API technology, enabling them to distribute their financial products and services online. The company offers, in addition to its API integrating ready-to-use banking and insurance micro-services, white-label platforms to industrialise the online distribution of banking, insurance and investment products. Particeep is a young innovative firm, winner of the 2017 and 2018 Banque et Innovation Fintech and Open Banking awards, elected Future Fintech European Star 2016 (ICT Awards 2016) and selected by Challenges in the 2016 ranking of 100 startups to invest in

WeGroup

Series A in 2020
WeGroup NV, founded in 2017 and headquartered in Gent, Belgium, operates a platform designed to enhance the connection between insurance providers and their digital customers. With additional offices in the United Kingdom and Poland, the company leverages data analytics and machine learning to optimize customer interactions. Its digital assistant, 'Louise,' operates around the clock to assist insurance intermediaries, service providers, and carriers in understanding client needs and risk profiles. Furthermore, WeGroup automates various processes, including claims handling and compliance, improving operational efficiency for its partners.

Monisnap

Seed Round in 2019
Monisnap SAS operates a digital instant money transfer platform and mobile application, enabling users to send money abroad quickly and efficiently. Founded in 2017 and based in Paris, France, the company targets the remittance market, addressing issues such as high fees and low customer satisfaction commonly associated with traditional services. Monisnap allows users to transfer money from Europe to various locations worldwide, facilitating transactions for individuals and businesses alike. The company is authorized to function as a banking intermediary by the French Financial Authority, highlighting its commitment to regulatory compliance and customer trust. Monisnap aims to provide a competitive alternative in the money transfer sector through its user-friendly platform and transparent fee structure.

RollingFunds

Series A in 2019
RollingFunds offers short term financing to small and medium enterprises. The company was founded in 2018 and is headquartered in Paris, France.

IPaidThat

Seed Round in 2019
IPaidThat automatically imports the invoices you receive, and compares them with your bank transactions, to make sure you do not forget anything.

Smile&Pay

Venture Round in 2018
Smile&Pay SAS, founded in 2007 and based in Paris, France, specializes in card payment solutions tailored for smartphones and tablets. The company provides electronic payment terminals designed for small and medium-sized merchants, enabling them to accept payments from a broad customer base without any fixed fees. Its product lineup includes PocketSmile, a compact mobile terminal that accepts all credit cards, and MaxiSmile, which features a printer and mobile GPRS capabilities. Additionally, Smile&Pay offers a service that allows users to track their receipts in real time through their computers or smartphones, catering to contractors, retailers, and the self-employed.

MoneyTrack

Funding Round in 2017
MONEYTRACK SAS provides a blockchain-based directed payment platform for insurance reimbursement services. Its platform validates payment contracts between financiers, issuers, beneficiaries, merchants, and payment institutions in the directed payment chain. The company was founded in 2018 and is based in Paris, France.

Geocorail

Venture Round in 2015
Géocorail développe et commercialise un produit innovant faisant travailler la mer à la protection du littoral : le Géocorail®. Ce procédé électrochimique breveté innovant consiste à créer une roche artificielle permettant de protéger les ouvrages marins et de lutter contre l’érosion du littoral.

Theraclion

Post in 2015
Theraclion Société anonyme develops, manufactures, and markets therapeutic ultrasound equipment. It offers an echotherapy solution that combines high-intensity focused ultrasound therapy with ultrasound as a system for locating target areas for the non-invasive treatment of benign tumours. The company also offers Echopulse for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners; and SONOVEIN, an echotherapy solution using therapeutic ultrasound for the treatment of varicose veins. It operates in approximately 20 countries worldwide. The company was founded in 2004 and is based in Malakoff, France.
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.

Actility

Series C in 2015
Actility is an industry leader in Low Power Wide Area Networks (LPWAN). ThingPark by Actility offers a carrier-grade IoT platform, with a growing ecosystem of partners; low-power, long-range wireless networks for sensors and devices; an operating system and middleware that enables web applications to connect seamlessly with data from different sensors; and a B2B e-commerce market featuring tested and approved IoT device, connectivity, and application partners. Actility is a founding member of the LoRa Alliance™.

Altimmune

Post in 2015
Altimmune, Inc. is a clinical stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of treatments for liver disease, immune modulation, and vaccines. The company's key product candidates include HepTcell, an immunotherapeutic for chronic hepatitis B infection, and NasoShield, an intranasal anthrax vaccine. Additionally, Altimmune is advancing NasoVAX, a recombinant intranasal vaccine, and AdCOVID, a single-dose intranasal vaccine targeting COVID-19. In the preclinical phase, it is developing ALT-801, a dual GLP-1/Glucagon receptor agonist for non-alcoholic steatohepatitis, and ALT-702, an immunostimulant for cancer treatment. Altimmune employs a proprietary non-invasive intranasal delivery technology that has demonstrated efficacy in both animal models and initial human studies. The company also engages in veterinary product development and collaborates with the University of Alabama at Birmingham to further its vaccine research.

SP3H

Venture Round in 2014
SP3H's values are in tune with the environmental and energetic stakes of the 21st century. For this reason, their company innovates in ground-breaking technology, which aims to reduce carbon dioxide levels and fuel consumption.

CoolGames

Series A in 2013
CoolGames B.V., founded in 2009 and based in Amsterdam with a satellite office in Tokyo, specializes in the development, distribution, and monetization of casual and social HTML5 games across various platforms, including smartphones, tablets, and desktop PCs. The company has published numerous high-quality games, including well-known titles like Angry Birds, Tetris, Snake, and Battleship, all accessible via cloud technology, which allows for immediate play without any downloads. In addition to its own game portfolio, CoolGames operates a games portal for media brands and game companies, as well as various direct-to-consumer web destinations aimed at casual gamers. The company serves a diverse clientele that includes media companies, websites, telecommunication operators, handset manufacturers, and game developers. CoolGames was previously known as BoosterMedia B.V. until it rebranded in February 2016.

Momac

Series B in 2013
Momac B.V. is a software provider specializing in customer engagement solutions for communication service providers (CSPs). The company develops a multi-screen platform that manages on-device user interfaces for mobile and web applications, facilitating the connection between CSPs and their customers. Momac's cloud-based platform enables the creation and management of personalized interfaces, helping CSPs reduce costs, increase revenue, and quickly launch solutions in the market. The mvolve platform supports mobile internet and application solutions for major operators, including Orange Group, Vodafone, and Telefonica, among others. With a presence in 27 countries and offices in the United States, the United Kingdom, the Netherlands, and France, Momac serves a diverse clientele, bridging the technology gap between internal data systems and customer care across various connected devices. Founded in 1997 and based in Rotterdam, the Netherlands, the company was previously known as YourNews B.V. and became a subsidiary of Sandvine Corporation in 2015.

Carbios

Funding Round in 2012
Carbios SAS is a green chemistry company based in Saint-Beauzire, France, that specializes in developing innovative bioprocesses for the biodegradation and recycling of plastics. Founded in 2011, the company focuses on creating fully biodegradable plastics with a controlled lifespan and has developed methods for recycling plastic waste, particularly PET, into reusable materials. Carbios produces enzymated pellets for biosourced and biodegradable plastics and is also involved in the production of polylactic acid. In collaboration with Novozymes, Carbios aims to enhance enzyme production for the efficient recycling of PET plastics and fibers, contributing to a more sustainable approach to plastic waste management and the development of competitive biosourced polymers.

SP3H

Venture Round in 2012
SP3H's values are in tune with the environmental and energetic stakes of the 21st century. For this reason, their company innovates in ground-breaking technology, which aims to reduce carbon dioxide levels and fuel consumption.

Pharnext

Venture Round in 2012
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

CoolGames

Funding Round in 2012
CoolGames B.V., founded in 2009 and based in Amsterdam with a satellite office in Tokyo, specializes in the development, distribution, and monetization of casual and social HTML5 games across various platforms, including smartphones, tablets, and desktop PCs. The company has published numerous high-quality games, including well-known titles like Angry Birds, Tetris, Snake, and Battleship, all accessible via cloud technology, which allows for immediate play without any downloads. In addition to its own game portfolio, CoolGames operates a games portal for media brands and game companies, as well as various direct-to-consumer web destinations aimed at casual gamers. The company serves a diverse clientele that includes media companies, websites, telecommunication operators, handset manufacturers, and game developers. CoolGames was previously known as BoosterMedia B.V. until it rebranded in February 2016.

Biokinesis

Funding Round in 2011
Biokinesis is a biotechnology company developing new treatments for cancer by targeting a specific kinesin found in several cancers.

Pharnext

Series B in 2011
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.
Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.

Utel

Venture Round in 2011
Utel SAS operates as a mobile application creator for social networking and collaborative services. The company provides Allokang, a Web platform that allows clients to buy or sell skills, talents, and expertise in the fields of legal, financial, academic support, IT, mental health issues, well-being, personal development, entertainment, astrology, clairvoyance, etc. It also offers Backstage SMS, a solution to start a game, a vote, etc.; a Web interface that allows animators to consult messages received from listeners; a photo and video function that allows listeners to send photos and video contents, while allowing animators to make related activities; and a solution that allows animators to monetize the traffic on community pages allowing listeners to participate in surcharged games with a click. The company was incorporated in 2000 and is based in Paris, France.

Actility

Seed Round in 2010
Actility is an industry leader in Low Power Wide Area Networks (LPWAN). ThingPark by Actility offers a carrier-grade IoT platform, with a growing ecosystem of partners; low-power, long-range wireless networks for sensors and devices; an operating system and middleware that enables web applications to connect seamlessly with data from different sensors; and a B2B e-commerce market featuring tested and approved IoT device, connectivity, and application partners. Actility is a founding member of the LoRa Alliance™.

Pharnext

Series A in 2010
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company’s products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer’s disease, as well as Parkinson’s disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

Immune Targeting Systems

Series A in 2010
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

Symetis

Series B in 2009
Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies for patients with heart valve diseases, particularly aortic valve stenosis. The company focuses on enhancing patient care and safety by providing simple and accurate solutions for heart valve replacement. Its proprietary Acurate Aortic Valve Replacement System features a distinctive self-positioning design, which facilitates easy implant positioning and alignment, thereby improving the overall ease of use for healthcare providers. Through its advanced transcatheter aortic valve implantation devices, Symetis aims to address severe cardiac valve conditions and enhance treatment options within the healthcare industry.

Eco-Carbone

Funding Round in 2008
Eco-Carbone provides consulting and project development services in the area of climate change mitigation.

Carmat

Funding Round in 2008
Carmat SA is a medtech company based in Vélizy-Villacoublay, France, specializing in the design and development of total artificial hearts for individuals suffering from end-stage biventricular heart failure. Founded in 2008, Carmat focuses on creating biocompatible, auto-regulated prosthetic hearts that closely mimic the function of natural human hearts. Its products are intended for patients with chronic terminal heart failure classified as New York Heart Association class IV, as well as those experiencing acute terminal heart failure after a significant myocardial infarction. The company aims to provide innovative therapeutic solutions for patients who are not candidates for heart transplants and have exhausted other treatment options. In addition to the artificial hearts, Carmat also develops associated power supply systems and control mechanisms for remote diagnosis.

OSEAD Maroc Mining

Private Equity Round in 2007
OSEAD Maroc Mining operates as a metal and mining platform. OSEAD is a holding company specialising in the prospecting, exploration and mining of mineral deposits. OSEAD’s main asset is Compagnie Minière de Touissit the second largest private mining operator in Morocco, which mines primarily lead and silver with some zinc.

PeopleCube

Venture Round in 2007
As of November 9, 2005, PeopleCube (UK) was acquired by PeopleCube, Inc. (formerly known as Meeting Maker, Inc.). PeopleCube provides intelligent on-demand workplace management solutions that help customers cut real estate, meeting services, travel, and energy costs based on actual workspace usage. Through its corporate headquarters in Framingham, Massachusetts, and offices throughout the world, PeopleCube supports 7,500 customers in small, medium, and large enterprises. PeopleCube helps businesses cut real estate, meeting services, travel and energy costs based on actual workspace usage. The UK predecessor, formerly known as The Internet Applications Group (UK), Ltd., was founded in 1995 and is based in Twickenham, the United Kingdom with an additional office in the Netherlands.

Neovacs

Venture Round in 2007
Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

Immune Targeting Systems

Series A in 2007
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normally used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.

Cytomics Pharmaceuticals

Series B in 2006
Cytomics Systems is a French private company that offers bio-pharmacology services. The company uses Yeast Micro-Lab technology, a protenomics tool, which enables to follow in-vitro deterioration of proteins. Cytomics Systems's research and development focuses on fungicidal infections, inflammatory illnesses, and cancers. Cytomics Systems, S.A was founded in 2000 and is based in Gif-sur-Yvette, France.

RF-iT Solutions

Series A in 2006
RF-iT Solutions GmbH provides radio frequency identification (RFID) software solutions and services. It develops and markets You-R® OPEN, an auto-ID software and RFID operating environment, which serves as a platform for system integrators, software manufacturers, and operators, as well as supports RFID infrastructure ranging from smart labels to readers, barcode scanners, label printers, and I/O devices. The company also provides RFID middleware; You-R Smart Fashion, a textile and apparel supply chain solution; You-R® DOCUTRACER, a Web-based application that stores data in a SQL-database for patent lawyers and hospitals; You-R® PHARMA, a solution for local packaging lines to capture item serial numbers, as well as the hierarchy of case/pallet serial numbers in pharmaceutical companies; You-R® RETAIL, an inventory solution for retailers; You-R® SECURE, a solution for manufacturer brand protection; and You-R® VIRTUAL TUNNEL, a solution the enables the allocation of single units to their packing units. In addition, it offers business case analysis, feasibility studies, testing, and technology consulting services. The company serves fashion, automotive, industrial manufacturing, pharmaceutical, retail, consumer packaged goods, logistics, asset management, and healthcare industries. RF-iT Solutions GmbH was founded in 2005 and is based in Graz, Austria. It has locations in Germany, France, and the United Kingdom.

Deinove SA

Funding Round in 2006
Deinove SA is a France-based company active in the renewable fuels sector. It specializes in the development and commercial exploitation of processes for production of biofuels and other compounds of industrial or pharmaceutical value.

Theradiag

Series C in 2005
Theradiag SA is a France-based company that specializes in the development, manufacturing, and marketing of in-vitro diagnostic products. Established in 1986 and located in Marne La Vallée, the company offers a range of solutions including autoimmunity reagents, quality control tools, and instruments for testing autoimmune and infectious diseases. Notable products include the SQA-V semen analyzer and the V-Sperm system for sample documentation. Theradiag also provides advanced instrumentation such as the Theralis platform, which integrates multiple diagnostic techniques, and the Theralis µ, designed for medium-sized laboratories. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and the LISA tracker, a tool for monitoring biotherapies.

AS Group

Funding Round in 2005
AS Group is a Parisian company and a spin-off of Deloitte, was a corporate performance software vendor.

Equitime

Funding Round in 2004
EquiTime provides organizations with Workforce Management Solutions which allow them to build, follow, count and analyse employee schedules while respecting the specificities of each profession. EquiTime renews the traditional concepts of time and activity management by adding the forecasting dimension to that of the actual work already done, which represents a source of increased productivity, and an improvement in the relations between company employees and customers.

Theradiag

Series B in 2003
Theradiag SA is a France-based company that specializes in the development, manufacturing, and marketing of in-vitro diagnostic products. Established in 1986 and located in Marne La Vallée, the company offers a range of solutions including autoimmunity reagents, quality control tools, and instruments for testing autoimmune and infectious diseases. Notable products include the SQA-V semen analyzer and the V-Sperm system for sample documentation. Theradiag also provides advanced instrumentation such as the Theralis platform, which integrates multiple diagnostic techniques, and the Theralis µ, designed for medium-sized laboratories. Additionally, the company offers therapeutic drug monitoring services for chronic inflammatory diseases and the LISA tracker, a tool for monitoring biotherapies.